Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Spruce Biosciences's Enterprise Value is $82.04 Mil.
Spruce Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-29.33 Mil. Therefore, Spruce Biosciences's EV-to-OCF for today is -2.80.
The historical rank and industry rank for Spruce Biosciences's EV-to-OCF or its related term are showing as below:
SPRB'
s EV-to-OCF Range Over the Past 10 Years
Min: -3.97 Med: 0.38 Max: 1.86
Current: -2.8
During the past 8 years, the highest EV-to-OCF of Spruce Biosciences was 1.86. The lowest was -3.97. And the median was 0.38.
SPRB's EV-to-OCF is ranked worse than 53.58% of 1409
companies
in the Biotechnology industry
Industry Median: -3.48
vs SPRB: -2.80
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Spruce Biosciences's PE Ratio (TTM) for today is calculated as:
Spruce Biosciences's share price for today is $46.87.
Spruce Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-37.608.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Spruce Biosciences EV-to-OCF Related Terms
Spruce Biosciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Spruce Biosciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Spruce Biosciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spruce Biosciences EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spruce Biosciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Spruce Biosciences's EV-to-OCF falls into.
Spruce Biosciences's current Enterprise Value is $82.04 Mil.
Spruce Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spruce Biosciences (SPRB) has a EV-to-OCF of -2.80 as of Aug. 08, 2026. According to the industry distribution chart, Spruce Biosciences ranks #755 out of 1409 companies in the Biotechnology industry, placing it in the top 53.6%.
Is Spruce Biosciences' EV-to-OCF too high?
Spruce Biosciences' current EV-to-OCF is -2.80. Based on the distribution chart, Spruce Biosciences ranks #755 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Spruce Biosciences has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spruce Biosciences' EV-to-OCF compare to VXRT and VTVT?
According to the Biotechnology industry distribution chart, Spruce Biosciences ranks #755 out of 1409 companies for EV-to-OCF. This places Spruce Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Spruce Biosciences's current EV-to-OCF is -2.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spruce Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Spruce Biosciences (SPRB) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.08, compared to a current price of $46.87 — trading 1048.8% above its estimated fair value. The current EV-to-OCF is -2.80. Spruce Biosciences' overall GF Score™ is 42/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Spruce Biosciences (SPRB), the current EV-to-OCF is -2.80 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spruce Biosciences (SPRB) Overvalued in 2026?
Based on GuruFocus' analysis, Spruce Biosciences stock appears to be overvalued.
The current stock price of $46.87 is trading 1048.8% above its estimated GF Value™ of $4.08.
GuruFocus considers Spruce Biosciences to be Significantly Overvalued.
Key valuation signals for SPRB:
EV-to-OCF: -2.80
GF Value™: $4.08 vs. price of $46.87 (1048.8% above fair value)
No single metric tells the full story. See the SPRB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
42GF Score
Get the complete analysis for SPRB
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRB has been successfully added to your 
